Ten billion cold Chinese patent medicine market TOP20 2 billion major varieties lead

At the time when the common cold is high, a new breakthrough in the field of Chinese patent medicines for colds-the first category 1 innovative drug was approved for listing
.
As the best-selling category in the retail market, the terminal sales of cold Chinese patent medicines in physical pharmacies in Chinese cities have exceeded 10 billion yuan, and China Resources Sanjiu Pharmaceutical has continued to rank as the top seller
.
Among the TOP20 products, the 2 billion variety of Ganmaoling granules hit a new high, the "magic drug" Shuanghuanglian oral liquid sold Waterloo, and 6 exclusive varieties were on the list
.
In the past five years, only one innovative Chinese medicine for colds has been approved for marketing in China
.
Ten billion cold Chinese patent medicine market! China Resources, Yiling Lead The cold is the most common disease, and it is even more "presumptuous" in the cold winter
.
In recent years, proprietary Chinese medicines for colds have become the best-selling category in the traditional Chinese medicine market in physical pharmacies
.
According to the latest data from Minet.
com, in 2020, the sales of Chinese patent medicines for colds in physical pharmacies in cities in China will exceed 11 billion yuan.
Sales in 2021 are expected to fall by 8.
51% year-on-year
.
Sales of cold proprietary Chinese medicines in physical pharmacies in cities in China (unit: 10,000 yuan) Source: Mi Nei.
com.
Competitive pattern of cold Chinese proprietary pharmacies in cities in China.
From the perspective of manufacturers, the top 5 cold Chinese patent medicines in the retail market for colds in 2021 are expected to be CR Sanjiu Pharmaceutical and Shijiazhuang Yiling Pharmaceutical, Yunnan Baiyao Group, China Resources Sanjiu (Chenzhou) Pharmaceutical, Guangzhou Xiangxue Pharmaceutical
.
Source of market pattern of TOP5 Chinese patent medicine manufacturers for terminal colds in physical pharmacies in Chinese cities.
Source: Meinenet.
com.
Competitive landscape of physical pharmacies in Chinese cities.
CR Sanjiu Pharmaceutical has ranked first for many consecutive years.
It is expected that its market share will rise to 23.
95% in 2021; Shijiazhuang Yiling Pharmaceutical Co.
, Ltd.
Although the second in the millennium, sales have increased rapidly in recent years, and the market share has exceeded 10%
.
TOP20 Chinese patent medicines for colds are released! One billion magic medicine Waterloo? TOP20 cold TCM products at physical pharmacies in Chinese cities Source: Meinenet.
com China city physical pharmacy terminal competition pattern In 2021, the sales of 17 products in the TOP20 cold TCM products at physical pharmacies in Chinese cities are expected to exceed 100 million yuan; Ganmaoling Granules are still the only variety with sales exceeding 2 billion yuan, and are expected to increase by more than 10%; after the sales of Lianhua Qingwen Capsules and Shuanghuanglian Oral Liquid exceed 1 billion yuan in 2020, they are expected to fall back in 2021
.
Six of the 20 products are exclusive varieties, namely Lianhua Qingwen Capsules and Lianhua Qingwen Granules of Yiling Pharmaceutical, Antiviral Granules of Sichuan Everbright Pharmaceutical, Four Seasons Antiviral Mixture of Shaanxi Haitian Pharmaceutical, Yunnan Baiyao Group Sanfengting Capsules and Jinlian Qingre Granules of Ningxia Qiyuan National Medicine
.
From the perspective of sales growth rate, the TOP20 products rose and fell by half
.
Five products including Ganmaoling Granules, Ganmaoling Capsules, Shangfengting Capsules, Ganmao Qingre Capsules, and Siji Ganmao Capsules increased by more than 10%.
Ganmao Qingre Capsules led the growth with 72.
68%, and Shangfengtang Capsules increased by 23.
51%
.
Sales of six products fell by more than 20%, mainly for drugs included in the "Drug List for Real-Name Registration Reporting During the Epidemic"
.
Among them, the decline of Shuanghuanglian oral liquid is expected to be 36.
48%, and its sales in medical institutions in the first half of the year are not optimistic
.
During the epidemic period, Shuanghuanglian Oral Liquid was listed as a recommended drug for epidemic prevention and control by many provinces and cities.
In 2020, sales in medical institutions and physical pharmacies have experienced explosive growth.
As the epidemic eases, the demand for Shuanghuanglian Oral Liquid has returned to normal
.
Sales of Shuanghuanglian Oral Liquid at Entity Pharmacies in Chinese Cities (Unit: 10,000 Yuan) Source: Mi Nei.
com Competitive Pattern of Entity Pharmacies in Chinese Urban Pharmacies The first Class 1 new Chinese medicine was approved! Kangyuan grabs the tens of billions market.
On November 15, Kangyuan Pharmaceutical issued an announcement stating that the company’s Yinqiao Qingre tablets were approved by the State Food and Drug Administration for the treatment of exogenous wind-heat common colds.

.
Kangyuan Pharmaceutical owns the independent and complete intellectual property rights of the new drug
.
The prescription of Yinqiao Qingre Tablets is based on the famous prescription "Yinqiao Baidu Decoction" for febrile diseases by Professor Wang Yongyan, an academician of the Chinese Academy of Engineering.
, And has the therapeutic effects of clearing lung heat, relieving throat pain, purging fire and detoxification, relieving cough and resolving phlegm
.
The approval of Yinqiao Qingre Tablets has further enriched the important product line of Kangyuan Pharmaceutical-the product echelon in the field of anti-infection
.
Previously, Kangyuan Pharmaceutical's product line had a variety of cold Chinese patent medicine products, including Shuanghuanglian soft capsules, antiviral oral liquid, Yinqiao Jiedu tablets, Ganmao fever granules, and antelope cold tablets
.
At the same time, the company has two applications for the listing of respiratory system drugs under review, including Reduning inhalation solution and Reduning granules
.
Since the beginning of this year, a total of 6 new Chinese medicines have been approved for marketing in China, including Yinqiao Qingre Tablets from Kangyuan Pharmaceutical, Yizhi Anshen Tablets from Yiling Pharmaceutical, Yiqi Tongqiao Pills from Tianjin Dongfang Huakang Pharmaceutical, and Guangdong Yifang Pharmaceutical Huashibaidu Granules, Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical, Qingfei Paidu Granules of China Academy of Chinese Medical Sciences
.
The source of new TCM drugs approved for marketing since 2021: Meinenet MED2.
0 China Drug Evaluation Database Kangyuan Pharmaceutical's Yinqiao Qingre Tablets are the first to be approved for listing since the implementation of the new TCM registration classification on July 1, 2020 Class 1.
1 innovative Chinese medicine is also the first innovative Chinese medicine for colds approved for marketing in the past five years after Jinhua Qinggan Granules were approved in 2016
.
It is worth noting that there are two other cold Chinese patent medicines under review, including Shenzhen Sanshun Pharmaceutical’s Caohong Capsules and Tasly’s Xiao Chaihu Decoction Dropping Pills
.
Data source: Meinenet database, company announcement Note: Meinenet China's urban physical pharmacy terminal competition pattern database covers physical pharmacies in 293 prefectures and above cities across the country (excluding county and rural physical pharmacies), and continuously monitors the entire category.
Edition city entity pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.